Clinical Trials
To fulfill our passion for clinical research, Advanced Neurology of Colorado has a research counterpart, Advanced Neurosciences Research, LLC.
Together, the research team participates in over 15 clinical trials, including those listed below. All trails noted below are active at this time and we are currently enrolling participants. Please sign up below for more information on the trials and/or how to participate.
For additional information, please visit http://www.clinicaltrials.gov
Clinical Research Interest Submission
To receive communication about currently enrolling or future studies, please enter your full name and best contact method below. You do not have to be a current patient with Advanced Neurology in order to submit your response.
Multiple Sclerosis Trials
EFC17919
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis (FREXALT)
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab
(SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis
https://clinicaltrials.gov/study/NCT06141473
EFC17504
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis (FREVIVA)
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With
Nonrelapsing Secondary Progressive Multiple Sclerosis
https://clinicaltrials.gov/study/NCT06141486
20230309
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety Between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis
TG1101-RMS401
Study to Evaluate Efficacy of a Modified Regimen of Ublituximab (ENHANCE)
Evaluating Efficacy of a Modified Regimen of Ublituximab
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple
Sclerosis (RMS) (ENABLE)
REal World ExperieNce With BRIUMVI® (UblituximAB-xiiy) Treated Patients: A Longitudinal REgistry Study (ENABLE)
https://clinicaltrials.gov/study/NCT06433752
Migraine Trials
CLIN-10200-454
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults (MERANTI)
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and
Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults
https://clinicaltrials.gov/study/NCT06625060
20668A
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
Interventional, Open-label Trial, Investigating the Effectiveness of Eptinezumab in Participants With Migraine and Previous
Inadequate Response to CGRP-targeting Therapies
C4951009
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention
in Children and Adolescents ≥ 6 to <18 Years of Age
https://clinicaltrials.gov/study/NCT05156398
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17
Years of Age) With Episodic Migraine (ATO EM PEDS)
A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for
the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 Years of Age.